Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) (VIEW1)

This study has been completed.
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00509795
First received: July 31, 2007
Last updated: December 20, 2012
Last verified: December 2012

July 31, 2007
December 20, 2012
August 2007
September 2010   (final data collection date for primary outcome measure)
Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) [ Time Frame: Baseline and at week 52 ] [ Designated as safety issue: No ]
Defined "maintenance of vision" as patients who lost fewer than 15 letters in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score compared to baseline.
Primary measure will be visual acuity changes compared to baseline
Complete list of historical versions of study NCT00509795 on ClinicalTrials.gov Archive Site
  • Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF [ Time Frame: Baseline and at week 52 ] [ Designated as safety issue: No ]
    Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning.
  • Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF. [ Time Frame: Baseline and at week 52 ] [ Designated as safety issue: No ]
    Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning.
  • Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF [ Time Frame: Baseline and at Week 52 ] [ Designated as safety issue: No ]
    The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.
  • Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF) [ Time Frame: Baseline and at week 52 ] [ Designated as safety issue: No ]
    CNV area values measured in square millimeters (mm^2); lower values represent better outcomes.
Secondary measures will be angiographic and anatomical changes compared to baseline.
Not Provided
Not Provided
 
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration

This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Macular Degeneration
  • Biological: ranibizumab
    Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
    Other Name: Lucentis
  • Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
    Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
    Other Names:
    • VEGF Trap-Eye
    • BAY86-5321
  • Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
    Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
    Other Names:
    • VEGF Trap-Eye
    • BAY86-5321
  • Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
    Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
    Other Names:
    • VEGF Trap-Eye
    • BAY86-5321
  • Active Comparator: ranibizumab 0.5mg Q4
    Intervention: Biological: ranibizumab
  • Experimental: aflibercept injection 2.0mg Q4
    Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
  • Experimental: aflibercept injection 0.5mg Q4
    Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
  • Experimental: aflibercept injection 2.0mg Q8
    Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1217
July 2011
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Signed Informed Consent.
  2. Men and women ≥ 50 years of age.
  3. Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye.
  4. Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) of: letter score of 73 to 25 (20/40 to 20/320) in the study eye at 4 meters.
  5. Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.
  6. Able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member. See Appendix J.4) understand and willing to sign the informed consent form.

Key

Exclusion Criteria:

  1. Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD except dietary supplements or vitamins.
  2. Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye, except dietary supplements or vitamins.
  3. Any prior treatment with anti-VEGF agents in the study eye.
  4. Total lesion size > 12 disc areas (30.5 mm^2, including blood, scars and neovascularization) as assessed by FA in the study eye.
  5. Subretinal hemorrhage that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. (If the blood is under the fovea, then the fovea must be surrounded 270 degrees by visible CNV.)
  6. Scar or fibrosis, making up > 50% of total lesion in the study eye.
  7. Scar, fibrosis, or atrophy involving the center of the fovea.
  8. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
  9. History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.
  10. Presence of other causes of CNV in the study eye.
  11. History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina,other than AMD, in either eye.
  12. Prior vitrectomy in the study eye.
  13. History of retinal detachment or treatment or surgery for retinal detachment in the study eye.
  14. Any history of macular hole of stage 2 and above in the study eye.
  15. Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as its unlikely to interfere with the injection.
Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00509795
VGFT-OD-0605
Yes
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Bayer
Study Director: Robert Vitti, MD Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP